Cell line development plays a key role in the identification of biological targets and commercial manufacturing of biotherapeutics. Despite its importance, the process faces a number of challenges, particularly when it comes to achieving monoclonality and assessing productivity. In this interview, we spoke with Darius Wilson, Product Manager of CellCelector Systems at Sartorius (Göttingen, Germany), to explore how technological advances, like the CellCelector CLD from Sartorius, are helping to overcome these issues to streamline and de-risk monoclonal cell line development. [ui-toggle title=”Meet the interviewee”] Darius Wilson Product Manager, Product Management BioAnalytics Workflow Sartorius Specializing in early identification of disease progression resulting from a dysregulated host response to localized bacterial or viral infections, Wilson is the author of 14 patents and numerous publications in fields such as gastrointestinal surgery, trauma-related complications, antibiotic guidance and emergency and intensive care medicine. He obtained his Ph.D. in physiology and pharmacology and an MBA from Glasgow Caledonian University (Scotland). [/ui-toggle] [ui-toggle title=”Questions”] Why is monoclonality so important in cell line development? How do researchers currently identify monoclonality, and what challenges do they face in doing so? How is productivity usually assessed in the cell line development workflow, and what issues can arise at this stage? Are there any other significant bottlenecks in the cell line development process? How can cell selection technologies like CellCelector CLD help to overcome these challenges? Do you have any advice on how to get the best results from CellCelector CLD? [/ui-toggle] Why is monoclonality so important in cell line development?…
